Podcasts about alimta

  • 11PODCASTS
  • 87EPISODES
  • 9mAVG DURATION
  • ?INFREQUENT EPISODES
  • Feb 14, 2023LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about alimta

Latest podcast episodes about alimta

The Busy Leader’s Podcast - A Catalyst for Inspired Action
65_Life Support: One Cancer Survivor's Journey into Patient Advocacy with John Hallick

The Busy Leader’s Podcast - A Catalyst for Inspired Action

Play Episode Listen Later Feb 14, 2023 25:12


John Hallick, founder and president of MET Crusaders and co-president of Biomarker Collaborative, joins the podcast to share the story of his journey into patient advocacy. In February 2018, John was diagnosed with stage IV non-small cell lung cancer. Several weeks later, the genetic tests came back, and the cancer was determined to be driven by the MET 14 skipping alteration. After learning from doctors that while there are many support groups for genetic alterations, there was none for his, John took action. He drew from his background as a serial entrepreneur to set up a patient-centric advocacy group for people with his particular genetic alteration. You'll hear about:John's story from his diagnosis of stage IV metastatic cancer to his treatment to where he is todayMET Crusaders, the advocacy group John founded that's dedicated to helping patients with the MET alteration live normal lives Biomarker Collaborative, a comprehensive body that represents all the advocacy groups, and their work connecting patients with the resources and support they need during what is likely the most traumatic point in their life       How others can find support and resourcesMost importantly, you'll meet a courageous individual who is using his own serious life challenge as a springboard to help, educate, and support others.https://biomarkercollaborative.org/John Hallick is a serial entrepreneur of several companies, all based around data warehousing, data mining, and individualized communications management. In December 2017, John developed what he thought might be the flu. It was diagnosed as an upper respiratory infection, and he was prescribed an antibiotic. After several weeks, the symptoms didn't go away, and he went back to the doctor's office. The second diagnosis was bronchitis, and he was prescribed prednisone. Again, the illness never went away. In January of 2018, he flew a helicopter four hours from Madison, WI, to Louisville, KY. The drive back to Madison was eight hours. He coughed on and off the entire drive back home. The next day, he went back to the doctor, and they decided to take an X-ray. The X-ray showed he had a mass in his right lung. As a note, nine months earlier he had a normal chest X-ray. At the end of January 2018, the Mayo Clinic in Rochester, MN, performed a complete workup, including PET scans, CT scans, brain MRIs, bone scans, and blood work. On February 1, 2018, at age 67, John was diagnosed with stage IV non-small cell lung cancer. Several weeks later, the genetic tests came back, and the cancer was determined to be driven by the MET 14 skipping alteration. His initial treatment was a combination of carboplatin, Alimta, and Keytruda every three weeks. John experienced all the normal side effects, including losing 65 pounds and half his hair, hearing loss, neuropathy on the bottom of his feet, no energy, and a significant loss of red blood cells. He was given two units of blood to get his red blood cells back into range. After four treatment sessions, carboplatin was removed from his treatment due to intolerability. After a total of five months of mixed results, it was decided for him to have one additional treatment and look for a clinical trial. After the last treatment, the immunotherapy started to work, and the tumors shrunk about one-third.   Now John had to make the decision of whether to stay on the current treatment plan or go on the trial. John decided to go on the capmatinib phase 2 clinical trial in July 2018. At first, the tumors shrank and then became stable. Targeted therapy returned his quality of life. Like all TKIs, capmatinib stayed effective for over three-and-a-half years. John trialed a MET antibody with limited success and is back on chemo and immune therapy.

Biotech 2050 Podcast
113. Envisioning VDC cancer treatment, Elisabet de los Pinos, CEO, Aura Biosciences

Biotech 2050 Podcast

Play Episode Listen Later Aug 3, 2022 20:57


Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundraising efforts, and today, she continues to lead Aura's strategy and operations. Prior to founding Aura, she worked in Eli Lilly & Co.'s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School. She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's 2009 “Top 40 under 40” list; as a Mass High Tech “Woman to Watch” in 2010; as a “Technology Pioneer” by the World Economic Forum in 2010; and as one of Goldman Sachs' “100 Most Intriguing Entrepreneurs” in 2014.

Cancer Interviews
048: Gary Brausen - Lung Cancer Survivor - Bloomington, Minnesota USA

Cancer Interviews

Play Episode Listen Later Feb 8, 2022 40:45


After being diagnosed with Stage 3B lung cancer, Gary Brausen went through a painful journey that included radiation, aggressive chemotherapy and the loss of a lung; but he survived, and now works hard to help others with their cancer journeys.

MesoTV Podcast: Conversations Impacting the Mesothelioma Community
Clinical trial assessing the addition of IMRT to pemetrexed (Alimta)/platinum based therapy

MesoTV Podcast: Conversations Impacting the Mesothelioma Community

Play Episode Listen Later Jan 26, 2021 33:17


Dr. Andreas Rimner of Memorial Sloan Kettering Cancer Center joins us to discuss a clinical trial "Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma." Dr. Rimner is a radiation oncologist specializing in thoracic cancers. He in interviewed by Mary Hesdorffer, expert nurse practitioner and executive director of the Mesothelioma Applied Research Foundation. Patients who need help with their diagnosis can contact Mary Hesdorffer, NP through the organization's website. The Mesothelioma Applied Research Foundation is the only national nonprofit organization dedicated to eradicating mesothelioma by providing patient services and education; funding peer-reviewed research; and advocating for government funding of mesothelioma research. More information about the organization is available at www.curemeso.org.

WEEI/NESN Jimmy Fund Radio-Telethon
OMF - Robert Thompson, 54, lung cancer, Fitchburg with Dr. Christopher Lathan, Faculty Director for Cancer Care Equity and thoracic oncologist, Dana-Farber 8-21-18

WEEI/NESN Jimmy Fund Radio-Telethon

Play Episode Listen Later Aug 21, 2018 8:29


Robert was lifting weights at his local YMCA before a routine doctor's appointment revealed he had stage 4 lung cancer.Robert's doctor estimated he only had one year to live. Following nine months of chemo- radiation, Robert's cancer went into remission. However, after only one month the cancer returned.Although a native of Alabama, Robert's wife and her family are from New England and recommended Robert seek treatment at Dana-FarberSince then, Robert has been under the care of Dr. Chris Lathan and his team.Robert started in an immunotherapy clinical that lasted for two years. He was removed from the trial in May 2018 due to the cancer's progression and is not being treated with Alimta. His scans have shown positive momentum. Throughout his treatment Robert thanks his wife, who has been there for him throughout it all.Dr. Christopher Lathan is an oncologist who specializes in cancers of the chest, including lung cancer.He sees patients and has published many research papers, mainly on cancer disparities for minorities.As Faculty Director for the Cancer Care Equity program at Dana-Farber, Dr. Lathan is committed to providing better access to cancer care and education to Boston communities.

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Monday, July 10 2017

FirstWord Pharmaceutical News

Play Episode Listen Later Jul 10, 2017 3:10


Today in FirstWord:

GRACEcast Lung Cancer Video
Immunotherapy Combinations

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 27, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

GRACEcast
Immunotherapy Combinations

GRACEcast

Play Episode Listen Later Apr 27, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

GRACEcast ALL Subjects audio and video
Immunotherapy Combinations

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 27, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

GRACEcast
Immunotherapy as First-Line Treatment

GRACEcast

Play Episode Listen Later Apr 26, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

GRACEcast ALL Subjects audio and video
Immunotherapy as First-Line Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 26, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

GRACEcast Lung Cancer Video
Immunotherapy as First-Line Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 26, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

GRACEcast
Maintenance Therapy for Advanced NSCLC

GRACEcast

Play Episode Listen Later Apr 21, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

GRACEcast ALL Subjects audio and video
Maintenance Therapy for Advanced NSCLC

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 21, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

GRACEcast Lung Cancer Video
Maintenance Therapy for Advanced NSCLC

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 21, 2016 4:35


Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

GRACEcast Lung Cancer Video
Histology-Specific Regimens - Squamous

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 17, 2016 4:02


Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

GRACEcast ALL Subjects audio and video
Histology-Specific Regimens - Squamous

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 17, 2016 4:02


Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

GRACEcast
Histology-Specific Regimens - Squamous

GRACEcast

Play Episode Listen Later Apr 17, 2016 4:02


Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

GRACEcast ALL Subjects audio and video
Histology-Specific Regimens - Adenocarcinoma

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 16, 2016 2:53


Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

GRACEcast Lung Cancer Video
Histology-Specific Regimens - Adenocarcinoma

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 16, 2016 2:53


Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

GRACEcast
Histology-Specific Regimens - Adenocarcinoma

GRACEcast

Play Episode Listen Later Apr 16, 2016 2:53


Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

GRACEcast Lung Cancer Video
What is the Role of Bevacizumab in Stage IV NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 15, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

GRACEcast
What is the Role of Bevacizumab in Stage IV NSCLC?

GRACEcast

Play Episode Listen Later Apr 15, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

GRACEcast ALL Subjects audio and video
What is the Role of Bevacizumab in Stage IV NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 15, 2016 3:46


Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

GRACEcast Lung Cancer Video
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 14, 2016 3:40


Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.

GRACEcast ALL Subjects audio and video
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 14, 2016 3:40


Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.

GRACEcast
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

GRACEcast

Play Episode Listen Later Apr 14, 2016 3:40


Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.

GRACEcast
Elderly Patients: Selecting Appropriate Systemic Treatment Agents

GRACEcast

Play Episode Listen Later Mar 3, 2016 6:54


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.

GRACEcast Lung Cancer Video
Elderly Patients: Selecting Appropriate Systemic Treatment Agents

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 3, 2016 6:54


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.

GRACEcast ALL Subjects audio and video
Elderly Patients: Selecting Appropriate Systemic Treatment Agents

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 3, 2016 6:54


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.

GRACEcast Lung Cancer Video
Predictive Testing for Chemotherapy Responsiveness

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

GRACEcast
Predictive Testing for Chemotherapy Responsiveness

GRACEcast

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

GRACEcast ALL Subjects audio and video
Predictive Testing for Chemotherapy Responsiveness

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

OIS Podcast
Aura Biosciences Offers Hope for Ocular Melanoma

OIS Podcast

Play Episode Listen Later Nov 22, 2015 24:12


Elisabeth “Eli” de los pinos was enjoying her job at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for the treatment of Lung cancer. But she took the leap, leaving corporate comfort to build Aura Biosciences from the ground up around viral-like synthetic nanoparticles that are closely related to wild type viruses in structure and behavior but lack any viral DNA. These empty protein shells resemble viruses but do not have the capability to replicate or integrate. Aura is leverage the technology to create AU-011, which can deliver potent cell-killing laser-activated molecule right to the point of ocular cancer. Aura says the molecule is activated by a standard ophthalmologic laser and treatment will be administered in an outpatient visit.

GRACEcast
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?

GRACEcast

Play Episode Listen Later Oct 30, 2015 2:01


Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.

GRACEcast ALL Subjects audio and video
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 30, 2015 2:01


Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.

GRACEcast Lung Cancer Video
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 30, 2015 2:01


Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.

GRACEcast ALL Subjects audio and video
What is Maintenance Therapy for Advanced NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 4, 2015 5:43


The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

therapy trial switch maintenance paramount nsclc jack west maintenance therapy gracecast cancergrace erlotinib tarceva alimta pemetrexed gcvl gcvllung
GRACEcast Lung Cancer Video
What is Maintenance Therapy for Advanced NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 4, 2015 5:43


The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

therapy trial switch maintenance paramount nsclc jack west maintenance therapy gracecast cancergrace erlotinib tarceva alimta pemetrexed gcvl gcvllung
GRACEcast
What is Maintenance Therapy for Advanced NSCLC?

GRACEcast

Play Episode Listen Later Oct 4, 2015 5:43


The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

therapy trial switch maintenance paramount nsclc jack west maintenance therapy gracecast cancergrace erlotinib tarceva alimta pemetrexed gcvl gcvllung
FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, Aug 26, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Aug 26, 2015 1:36


FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Thursday, June 25, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Jun 25, 2015 1:43


GRACEcast ALL Subjects audio and video
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast Lung Cancer Video
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast ALL Subjects audio and video
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 23, 2014 29:51


Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

GRACEcast
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1

GRACEcast

Play Episode Listen Later Oct 23, 2014 29:51


Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

GRACEcast Lung Cancer Video
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 23, 2014 29:51


Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

GRACEcast Lung Cancer Video
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast ALL Subjects audio and video
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast
I'm Very Optimistic. For the First Time.

GRACEcast

Play Episode Listen Later Sep 11, 2014 1:32


Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014

GRACEcast Lung Cancer Video
I'm Very Optimistic. For the First Time.

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 11, 2014 1:32


Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014

GRACEcast ALL Subjects audio and video
I'm Very Optimistic. For the First Time.

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 11, 2014 1:32


Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014

GRACEcast Lung Cancer Video
Does Gilotrif Help EGFR Positive Lung Cancer Patients?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 18, 2014 8:16


An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

GRACEcast
Does Gilotrif Help EGFR Positive Lung Cancer Patients?

GRACEcast

Play Episode Listen Later Jun 18, 2014 8:16


An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

GRACEcast ALL Subjects audio and video
Does Gilotrif Help EGFR Positive Lung Cancer Patients?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 18, 2014 8:16


An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

GRACEcast Lung Cancer Video
TH 302: New Drug May Make Tumors Less Resistant to Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 4, 2014 1:26


Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

GRACEcast ALL Subjects audio and video
TH 302: New Drug May Make Tumors Less Resistant to Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 4, 2014 1:26


Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

GRACEcast
TH 302: New Drug May Make Tumors Less Resistant to Treatment

GRACEcast

Play Episode Listen Later Jun 4, 2014 1:26


Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Friday, May 16, 2014

FirstWord Pharmaceutical News

Play Episode Listen Later May 16, 2014 14:43


Today in FirstWord:

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, April 2, 2014

FirstWord Pharmaceutical News

Play Episode Listen Later Apr 2, 2014 6:36


Today in FirstWord:

GRACEcast ALL Subjects audio and video
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 15, 2013 12:50


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

GRACEcast Lung Cancer Video
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 15, 2013 12:50


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

GRACEcast
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

GRACEcast

Play Episode Listen Later Jun 15, 2013 12:50


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

GRACEcast
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

GRACEcast

Play Episode Listen Later Jun 13, 2013 6:36


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

GRACEcast ALL Subjects audio and video
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 13, 2013 6:36


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

GRACEcast Lung Cancer Video
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 13, 2013 6:36


Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

GRACEcast
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)

GRACEcast

Play Episode Listen Later Apr 7, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast Lung Cancer Video
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 7, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

GRACEcast

Play Episode Listen Later Apr 7, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast ALL Subjects audio and video
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 7, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast ALL Subjects audio and video
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 7, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast Lung Cancer Audio
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Apr 6, 2013 3:43


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

GRACEcast Lung Cancer Video
Case in Point: Recommendation for Adjuvant Chemotherapy for Lung Cancer Based on High Risk Tumor Features

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 12, 2013 4:45


Dr. Jack West describes the factors that contribute to a recommendation for or against post-operative (adjuvant) chemotherapy for a patient with resected early stage non-small cell lung cancer.

GRACEcast Lung Cancer Video
ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 19, 2012 6:50


Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

GRACEcast Lung Cancer Audio
ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 19, 2012 6:50


Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

GRACEcast Lung Cancer Video
ASCO 2012 Lung Cancer Highlights: Dr. Mark Socinski on PARAMOUNT Continuation Maintenance Therapy Trial (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 16, 2012 8:37


Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

GRACEcast Lung Cancer Audio
ASCO 2012 Lung Cancer Highlights: Dr. Mark Socinski on PARAMOUNT Continuation Maintenance Therapy Trial (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 16, 2012 8:37


Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

GRACEcast Lung Cancer Video
Lung Cancer Highlights in 2011: ALK and New Molecular Targets (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 18, 2012 8:22


Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, with this podcast focusing on ALK rearrangements and new molecular targets in lung cancer.

GRACEcast Lung Cancer Audio
Lung Cancer Highlights in 2011: ALK and New Molecular Targets (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Mar 18, 2012 8:21


Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, with this podcast focusing on ALK rearrangements and new molecular targets in lung cancer.

GRACEcast Lung Cancer Video
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 3 (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 9, 2010 16:38


Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.

GRACEcast Lung Cancer Audio
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 3 (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Sep 9, 2010 16:40


Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.

GRACEcast Lung Cancer Audio
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 2 (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 30, 2010 17:53


Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.

GRACEcast Lung Cancer Video
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 2 (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 30, 2010 17:53


Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.

GRACEcast Lung Cancer Video
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 19, 2010 20:05


Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for a patient with advanced squamous cell NSCLC.

GRACEcast Lung Cancer Audio
Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 19, 2010 20:06


Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for a patient with advanced squamous cell NSCLC.